Pluri (PLUR) Competitors $5.05 +0.04 (+0.80%) Closing price 07/16/2025 03:58 PM EasternExtended Trading$5.05 0.00 (0.00%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PLUR vs. CYBN, VYGR, IMAB, ACOG, LFVN, DERM, IPHA, ENTA, SPRO, and NVCTShould you be buying Pluri stock or one of its competitors? The main competitors of Pluri include Cybin (CYBN), Voyager Therapeutics (VYGR), I-Mab (IMAB), Alpha Cognition (ACOG), Lifevantage (LFVN), Journey Medical (DERM), Innate Pharma (IPHA), Enanta Pharmaceuticals (ENTA), Spero Therapeutics (SPRO), and Nuvectis Pharma (NVCT). These companies are all part of the "pharmaceutical products" industry. Pluri vs. Its Competitors Cybin Voyager Therapeutics I-Mab Alpha Cognition Lifevantage Journey Medical Innate Pharma Enanta Pharmaceuticals Spero Therapeutics Nuvectis Pharma Pluri (NASDAQ:PLUR) and Cybin (NYSE:CYBN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation. Do insiders & institutionals believe in PLUR or CYBN? 16.6% of Pluri shares are held by institutional investors. Comparatively, 17.9% of Cybin shares are held by institutional investors. 25.9% of Pluri shares are held by company insiders. Comparatively, 15.0% of Cybin shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts recommend PLUR or CYBN? Pluri presently has a consensus target price of $12.00, indicating a potential upside of 137.62%. Cybin has a consensus target price of $85.00, indicating a potential upside of 1,030.32%. Given Cybin's stronger consensus rating and higher probable upside, analysts clearly believe Cybin is more favorable than Pluri.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Cybin 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Does the media favor PLUR or CYBN? In the previous week, Pluri and Pluri both had 1 articles in the media. Pluri's average media sentiment score of 0.93 beat Cybin's score of 0.52 indicating that Pluri is being referred to more favorably in the media. Company Overall Sentiment Pluri Positive Cybin Positive Which has more risk & volatility, PLUR or CYBN? Pluri has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Comparatively, Cybin has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Is PLUR or CYBN more profitable? Cybin has a net margin of 0.00% compared to Pluri's net margin of -2,563.29%. Cybin's return on equity of -37.58% beat Pluri's return on equity.Company Net Margins Return on Equity Return on Assets Pluri-2,563.29% -4,191.91% -85.40% Cybin N/A -37.58%-36.59% Which has preferable earnings and valuation, PLUR or CYBN? Pluri has higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPluri$330K120.43-$20.89M-$5.53-0.91CybinN/AN/A-$57.88M-$3.88-1.94 SummaryCybin beats Pluri on 9 of the 15 factors compared between the two stocks. Get Pluri News Delivered to You Automatically Sign up to receive the latest news and ratings for PLUR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PLUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLUR vs. The Competition Export to ExcelMetricPluriMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$39.47M$2.90B$5.51B$9.31BDividend YieldN/A2.46%4.25%4.09%P/E Ratio-0.9120.3628.1219.69Price / Sales120.43298.74439.46100.25Price / CashN/A42.3835.5357.53Price / Book5.057.768.235.67Net Income-$20.89M-$55.11M$3.23B$257.51M7 Day Performance-6.65%0.19%-0.52%-0.16%1 Month Performance19.10%10.80%6.71%9.89%1 Year Performance-11.87%-0.68%27.10%15.08% Pluri Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLURPluri3.2867 of 5 stars$5.05+0.8%$12.00+137.6%-13.7%$39.47M$330K-0.91150Positive NewsGap DownCYBNCybin2.5998 of 5 stars$7.70-2.2%$86.00+1,017.5%N/A$176.13MN/A-1.7550VYGRVoyager Therapeutics3.996 of 5 stars$3.15+3.6%$13.39+325.1%-64.0%$173.82M$80M-2.15100News CoverageIMABI-Mab2.842 of 5 stars$2.13+1.7%$6.00+182.4%+31.9%$173.53M$3.89M0.00380ACOGAlpha Cognition1.733 of 5 stars$10.75-4.4%$20.00+86.0%N/A$172.22MN/A-8.96N/ALFVNLifevantage4.2344 of 5 stars$13.43-1.2%$30.50+127.1%+97.8%$169.02M$200.16M19.46260News CoveragePositive NewsDERMJourney Medical2.4054 of 5 stars$7.23+1.8%$9.50+31.4%+21.8%$165.55M$56.13M-18.2290IPHAInnate Pharma2.5992 of 5 stars$1.79-1.6%$11.00+514.5%-16.3%$165.00M$21.77M0.00220ENTAEnanta Pharmaceuticals3.755 of 5 stars$7.77-1.5%$18.00+131.7%-56.1%$164.26M$67.64M-1.69160News CoverageSPROSpero Therapeutics3.9219 of 5 stars$2.94+1.2%$5.00+70.4%+64.7%$164.10M$47.98M-2.29150NVCTNuvectis Pharma3.3079 of 5 stars$7.82-0.4%$17.00+117.5%+18.4%$163.36MN/A-6.928Positive News Related Companies and Tools Related Companies Cybin Competitors Voyager Therapeutics Competitors I-Mab Competitors Alpha Cognition Competitors Lifevantage Competitors Journey Medical Competitors Innate Pharma Competitors Enanta Pharmaceuticals Competitors Spero Therapeutics Competitors Nuvectis Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PLUR) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pluri Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pluri With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.